TCM Biotech International Corp.

As of December 31, 2025, TCM Biotech International Corp. has 59.05M shares outstanding.

As of December 31, 2025, TCM Biotech International Corp. maintains a current ratio of 7.47, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.07, indicating elevated leverage, while an interest coverage ratio of 20.84 demonstrates strong ability to service its debt obligations.

Over the twelve months ended December 31, 2025, TCM Biotech International Corp. posted a return on equity (ROE) of 3.10, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 1.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.61, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.99, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.75 indicates how many times TCM Biotech International Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended December 31, 2025. That works out to an effective tax rate of 14.03, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

As of the close on May 5, 2026, TCM Biotech International Corp.'s stock has gained approximately 212.50% over the past 52 weeks. The 50-day moving average sits at 182.12, while the 200-day moving average is 148.72.

Over the twelve months ended December 31, 2025, TCM Biotech International Corp. posted a gross margin of 46.24, reflecting its pricing power and cost economics. The operating margin of 2.63 and net profit margin of 2.80 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. The dividend payout ratio of 107.81 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

TCM Biotech International Corp.'s most recent stock split took place on July 20, 2023 with a 5000:5153 split ratio.

As of December 31, 2025, TCM Biotech International Corp. has an Altman Z-Score of 1.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.